News
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were ...
Unlike Drs. Adam Cifu and John Mandrola, I do not constantly boast of my "nuance" or claim to be a master of "clinical ...
Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...
11d
Zacks Investment Research on MSNMRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 ...
Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months through 11 years. Novavax's COVID shot (Nuvaxovid) is fully approved for people ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...
Moderna stock surged on Tuesday amid what has been a lively past few days for the pharmaceutical industry. The tumultuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results